Vineet laboratories Limited has reported a significant turnaround in its Q3FY26 financial performance, posting a net profit of ₹85.07 lakh compared to a substantial loss of ₹570.70 lakh in the corresponding quarter of the previous fiscal year. The pharmaceutical company's Board of Directors approved these unaudited standalone financial results for the quarter and nine months ended December 31, 2025, during their meeting held on February 14, 2026.

Financial Performance Overview

The company's quarterly financial metrics demonstrate a mixed performance with profitability recovery despite revenue challenges:

Nine-Month Performance Analysis

For the nine-month period ended December 31, 2025, Vineet Laboratories achieved remarkable improvement in profitability:

Cost Management and Operational Efficiency

The company's profitability turnaround can be attributed to effective cost management strategies. Total expenses decreased significantly to ₹1,487.79 lakh in Q3FY26 from ₹2,380.59 lakh in Q3FY25, representing a 37.5% reduction. Key expense components showed the following changes:

• Cost of materials consumed: ₹971.66 lakh vs ₹1,806.85 lakh (46.2% decrease)
• Other expenses: ₹233.99 lakh vs ₹375.36 lakh (37.7% decrease)
• Finance costs: ₹109.46 lakh vs ₹95.14 lakh (15.1% increase)
• Employee benefits expenses: ₹103.71 lakh vs ₹121.25 lakh (14.5% decrease)

Board Decisions and Equipment Investments

During the February 14, 2026 board meeting, directors approved several strategic decisions beyond the financial results. The Board ratified advances and approved payments to vendors for Quality Control equipment and Purified RO Water equipment. These investments, made in February 2026, are designated for installation in the company's new production facility, which was previously mentioned in the Rights Issue Letter of Offer dated December 17, 2025.

Capital Structure and Share Information

Vineet Laboratories maintains a stable capital structure with paid-up equity share capital of ₹921.90 lakh, consisting of shares with a face value of ₹10 each. The company operates primarily in the Active Pharmaceutical Ingredients and intermediates segment, with no separate reportable business segments requiring disclosure under Ind AS 108.

The financial results have been prepared in accordance with Indian Accounting Standards and received an unqualified review report from statutory auditors NSVR & Associates LLP. The results are available on the company's website and stock exchange platforms for stakeholder access.

Vineet Laboratories Limited successfully concluded its Extra-Ordinary General Meeting on February 07, 2026, with shareholders providing overwhelming support for a key board appointment. The meeting, conducted through video conferencing from 11:00 AM to 11:45 AM, focused on a single special resolution regarding the appointment of an Independent Director.

Meeting Overview and Participation

The EGM was held in compliance with regulatory requirements under the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the Companies Act, 2013. With a record date of January 30, 2026, the company had 10106 total shareholders eligible to participate.

The meeting witnessed participation from 51 shareholders through video conferencing, including 12 from the promoter and promoter group category and 39 from the public category. No shareholders attended the meeting in person or through proxy.

Resolution Details and Voting Results

The sole agenda item was a special resolution for the appointment of Ms. Jasmin Kunal Tailor (DIN: 10794164) as an Independent Director of the company. The promoter and promoter group were not interested in this particular resolution, ensuring independent decision-making by shareholders.

E-Voting Process and Scrutinizer Report

The voting process was conducted electronically through Central Depository Services Limited (CDSL) platform. Remote e-voting was available from February 04, 2026, at 09:00 AM to February 06, 2026, at 05:00 PM, followed by e-voting facility during the EGM for eligible shareholders.

Mr. Jineshwar Kumar Sankhala from P S Rao & Associates served as the scrutinizer for the meeting. He was appointed by the Board of Directors on January 07, 2026, and submitted his report on February 07, 2026, confirming the validity and transparency of the voting process.

Resolution Outcome

The special resolution was passed with overwhelming support, receiving 1219216 votes in favor representing 99.99% of total valid votes cast. Only 78 votes were cast against the resolution, representing 0.01% of the total. The strong approval rate demonstrates shareholder confidence in the proposed appointment.

The voting results and scrutinizer's report have been made available on the company's website at www.vineetlabs.co.in and on CDSL's e-voting portal at www.evotingindia.com , ensuring transparency and regulatory compliance.